StreetAlpha.app
Home › Stocks › TPST

Tempest Therapeutics, Inc. (TPST)

$0.33
▼ −5.13%
LAST CLOSE · NOV 17

Tempest Therapeutics develops cancer treatments, including immune cell therapies and small molecule drugs, for patients with blood cancers and solid tumors. It last closed at $0.33 on Nov 17, down 5.13% on the day.

AI Auto Pilots
Is TPST in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$40.6M
EPS (diluted)
−$3.16
Valuation
Market cap
$6.5M
20.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$897K
At Sep 30
Shareholder equity
−$1.8M
Shares outstanding
20.0M
At Nov 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$28.3M−$28.3MFY2021FY2022: −$35.7M−$35.7MFY2022FY2023: −$29.5M−$29.5MFY2023FY2024: −$41.8M−$41.8MFY2024FY2025: −$26.3M−$26.3MFY2025

From TPST's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Last report
Nov 13
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated TPST in the past 90 days, not enough for a consensus
Average 12-month target
$7.00
▲ 2038.7% upside

Based on 1 analyst who set a price target on TPST in the past 90 days. The average target is $7.00, with a high of $7.00 and a low of $7.00, compared with the last close of $0.33.

Low $7.00Avg $7.00High $7.00
Blue marker: last close $0.33
Highest target$7.00
Average target$7.00
Lowest target$7.00
Latest rating changes
HC Wainwright & Co.Maintained
Sep 24Buy$7
DateFirmActionRatingPrice target
Sep 24HC Wainwright & Co.MaintainedBuy$7
Loading…

Technical Analysis

TPST · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 36% below its 20 day and 101% below its 50 day average. It is 316% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the Pivot at $0.32, and the nearest resistance the Pivot R1 at $0.34.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 16.4%/day
Key levels
$9.7552 week high+2854.5%
$1.36200 day average+312.1%
$0.84100 day average+154.5%
$0.6650 day average+100.0%
$0.48Swing high (Nov 11)+45.5%
$0.4420 day average+33.3%
$0.34Pivot R1+3.0%
$0.33Last close
$0.32Pivot−3.0%
$0.32Pivot S1−3.0%
$0.3152 week low−6.1%
Indicators
RSI (14)23.20Oversold below 30Oversold
MACD-0.09Below its signal lineBearish
Stochastic9.3Near the bottom of its rangeOversold
ADX (14)28.3Trending down
Williams %R-94.0Oversold below −80, overbought above −20Oversold
CCI (20)-128.8Oversold below −100, overbought above 100Oversold
Rate of change−30.1%Change over 10 sessionsBearish
ATR (14)$0.05Typical daily range, 16.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TPST

What happened before

See how TPST did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TPST usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TPST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in TPST in the last 90 days.

Loading…

See today’s whale options flow across the market →

TPST Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●10 buying vs 9 selling
  • ▼Held by funds -2.4 pts
  • ▲Funds holding +3
  • ▼Superinvestors: 0 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2421+14.3%
In funds' top 1012−50.0%
Held by funds4.1%6.5%−2.4 pts
New / increased8 / 24 / 5+11.1%
Reduced / sold out4 / 53 / 5+12.5%
Put/call ratio–––
SuperinvestorsKen GriffinSold out
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TPST institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TPST is in one of them and how their past TPST trades turned out.

TPST in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TPST in an article yet. Here's the latest on the wider market.

About Tempest Therapeutics

Tempest Therapeutics is a biotechnology company based in Brisbane, California, that develops treatments for cancer. Its pipeline includes cell therapies that use engineered immune cells to target tumors, including a candidate for multiple myeloma, a blood cancer. It also develops small molecule drugs, including one being prepared for late-stage testing in liver cancer and another for people with a rare inherited condition that raises the risk of certain cancers. Its candidates are still in development and not approved for sale, and they are aimed at patients with these cancers and conditions.

Headquarters
Brisbane, CA